FDA Approves Relacorilant with nab-Paclitaxel for Platinum-Resistant Epithelial Ovarian, Fallopian Tube, Or Primary Peritoneal Cancer
esmo - Evidence for efficacy is based on the findings from the ROSELLA study
AI Summary: The FDA granted marketing authorization for relacorilant in combination with nab‑paclitaxel to treat platinum‑resistant epithelial ovarian, fallopian tube and primary peritoneal cancers. Regulators cited clinical benefit in a difficult‑to‑treat population, providing an additional therapeutic option for patients with limited choices and marking an important regulatory milestone.
Related Stories
Bristol Myers Squibb wins first-in-class approval for protein‑degrader myeloma therapy / 15 days
Belzutifan plus pembrolizumab gains approval for adjuvant RCC / 5 wks
FDA greenlights datopotamab deruxtecan for metastatic TNBC / 2 months
FDA approves belzutifan (Welireg) plus pembrolizumab for adjuvant RCC / 2 months
FDA clears first all-oral regimen for certain newly diagnosed AML patients / 2 months
VOLGA Phase III shows survival benefit for bladder cancer neoadjuvant combo / 3 months
FDA expands approval of Lu‑177 radiopharmaceutical for prostate cancer / 22 days
StackHealth RSS
You can now follow topics by RSS - browse the complete list of topics, people, and organizations. Or, try Drug Development, Pharmaceuticals, Weight Loss, Olfaction and look for the RSS link.
StackHealth Time Machine